WorkflowClinical Development

Learn · the schedule

Schedule of activities in a clinical trial: how to build one

The schedule of activities is the protocol's control table, not an illustration of it. Visits across, procedures down, a window on every column — and it silently decides what sections 5, 8 and 10 are allowed to say. This guide builds one, then runs the checks it has to survive, using Clinical Protocol Authoring's worked Phase 3 example.

Updated · 12 min read

See one case, screen by screen →
Watch with transcript →

The schedule of activities in a clinical trial is the table that lists every visit across the top and every procedure down the side, with an allowable window on each visit. Building one is not a layout job: because every other section quotes it, the table decides which eligibility tests exist, when each endpoint is measured and how often safety is checked, so it has to be built before the prose and tested against the endpoints afterwards. It is hard for a dull reason — it is usually adapted from a past study whose visits were in different weeks. Clinical Protocol Authoring is Botminds' software for drafting trial protocols, and it opens on this table, with the fourteen sections drafting beside it and a running check that every endpoint has a visit to be measured at.

Two names for one table, before anything else. ICH M11 calls it the schedule of activities; most sponsors, and the sample draft used here, call it the schedule of assessments; ICH E6(R3) asks for "a description of the schedule of events"; SPIRIT 2025 calls it the participant timeline. They are the same artefact, and this guide uses the template's name for it. The worked example throughout is the invented study VLT-302 — a Phase 3 trial of Veltrimab in moderate-to-severe plaque psoriasis — and its people, sponsor and data are sample data, not a customer's.

What is a schedule of activities in a clinical trial?

It is the operational contract between the protocol and the site. A coordinator who has to know what happens on a given morning does not read section 8; they read one column of this table. That is why ICH M11 places it at section 1.3, in the first few pages: "the Template is designed with the most vital information for execution (e.g., Synopsis, Schema, Schedule of Activities) near the front," because the needs of investigators and site staff were given primary consideration.

It is also the only place in the protocol where the whole trial is visible at once. Section 5 says who may enrol; section 6 says what they are given; section 8 says how each assessment is performed; section 10 says what will be analysed. Only the schedule says when, and in what combination, and therefore what a single participant's Tuesday looks like.

One schedule of activities: eleven visits, fifteen procedures, a burden score on every column

The schedule of assessments for the invented study VLT-302 in Clinical Protocol Authoring, headed Section 1.3, Table 1. Eleven visit columns run across — screening at day minus 35 to minus 1, Day 1 at Week 0, then Weeks 4, 8, 12 and 16 with a plus or minus 3 day window, Weeks 20, 28, 40 and 52 with a plus or minus 7 day window, and a follow-up visit at Week 60. Fifteen procedure rows run down in five groups: screening, efficacy, safety, pharmacokinetics and immunogenicity, and trial intervention. Each row shows its minutes and, where relevant, millilitres of blood. A bar above each visit column gives that visit's patient burden score: 44, 59, 53, 14, 34, 52, 30, 53, 32, 40 and 9 against a limit of 60. A footer reads 11 visits, 15 procedures, blood over the trial 122 millilitres, most in any 8 weeks 52 millilitres of 550, hardest visit Day 1 at 59.
Sample protocol data in Clinical Protocol Authoring. The right-hand column of each row names the protocol section that row is written into, which is how the table stays tied to the prose.

Visits across, procedures down: how the table is laid out

The convention is near-universal and worth following even where a sponsor template is silent. Columns are visits in time order, each carrying its study day or week, its window and its period. Rows are procedures, grouped by why they are done — screening, efficacy, safety, pharmacokinetics and immunogenicity, intervention — because a reader scanning for one kind of obligation scans by group. A tick marks the intersection; a footnote carries the exception.

Two columns are usually worth adding beyond the ticks. The first is what each procedure costs a participant: minutes on site, millilitres of blood, needle sticks. The second is which section of the protocol the row is written into, so that a change to the table has an obvious destination in the prose. Neither is required by anyone. Both make the table reviewable rather than merely correct.

The fifteen procedure rows of one Phase 3 schedule, and what each one asks

ProcedureGroupWhat it costs a participantWritten into
Informed consentScreening30 min, screening visit onlySection 11, oversight and consent
Eligibility criteriaScreening10 min, screening and Day 1Section 5, trial population
IGRA tuberculosis testScreening3 mL, screening only, taken with the screening drawSection 5, trial population
PASIEfficacy10 min, every visit from screeningSection 8, assessments
sPGAEfficacy5 min, every visit from screeningSection 8, assessments
BSAEfficacy5 min, every visit from screeningSection 8, assessments
DLQIEfficacy5 min, from Day 1Section 8, assessments
Vital signsSafety10 min, every visitSection 8, assessments
Clinical laboratory testsSafety10 min and 12 mL, taken with the other draws of that visitSection 8, assessments
Pregnancy testSafety5 min, every visit for participants of childbearing potentialSection 8, assessments
Adverse eventsSafety5 min, every visit and every contactSection 9, adverse events
Concomitant medicationSafety5 min, every visitSection 6, intervention and concomitant therapy
PK sample, pre-dosePK and immunogenicity4 mL, dosing visits, before the injectionSection 8, assessments
Anti-drug antibodiesPK and immunogenicity5 mL, at the sampling visitsSection 8, assessments
Veltrimab or placebo, subcutaneousTrial intervention30 min including observation, at each dosing visitSection 6, intervention
Sample protocol data in Clinical Protocol Authoring, on the invented study VLT-302. Minutes and millilitres come from the sponsor's own procedure table; the final column is how this draft ties each row to the section that describes it.

What belongs in it — and what ICH M11 says must be in it

The template's instruction for section 1.3 is five clauses long and every one of them is a rule a real schedule breaks somewhere. Read it slowly; it is the shortest useful checklist in the whole document.

The ICH M11 instruction for the schedule of activities, clause by clause

  1. “the procedures that will be accomplished at each trial visit”

    Every procedure, at every visit. A procedure a site performs but the table omits is a procedure nobody has costed, consented for or scored.

  2. “and all contact with participants (e.g., telephone contacts)”

    Telephone calls, diary reminders, remote questionnaires. Contact without a visit is still contact, and still belongs as a column.

  3. “any tests that are used for eligibility, participant randomisation or stratification, or decisions on trial intervention discontinuation”

    The tests that make a decision. These are the rows a reader checks against sections 5, 6 and 7, so they must be identifiable in the table rather than buried in a group.

  4. “Allowable windows should be stated for all visits and procedures”

    All of them. A window stated only in the text leaves the table saying something stricter than the protocol means.

  5. “A tabular format is recommended”

    Not a paragraph, not a diagram alone. And where sampling is extensive — serial pharmacokinetics, for example — a separate table may be added rather than crushed into this one.

Quotations from the ICH M11 template, Step 4, section 1.3. The second column of each row is our reading of what the clause costs a writer in practice.Source: ICH M11 template, Step 4

The third clause is the one most often missed, because the tests it names look like ordinary rows. An IGRA tuberculosis test is a screening laboratory result in most templates; in this trial it decides eligibility, which means section 5 has to say what result excludes a participant and the table has to show that the test happens before randomisation. The same applies to a stratification measure and to any test that triggers discontinuation.

What are visit windows, and why they belong in the table

A visit window is the span of days around a nominal visit day in which the visit may still take place and still count. It exists because participants have jobs, sites have holidays, and a trial that treats every scheduled day as absolute converts ordinary life into a stream of deviations.

Windows are usually tighter where a measurement matters and looser where it does not. In the sample trial, visits through Week 16 — the co-primary endpoint visit — carry a window of plus or minus three days; from Week 20 to Week 52 the window opens to plus or minus seven. Screening is expressed differently again, as a span rather than a tolerance: day minus 35 to day minus 1.

Two mistakes recur. The first is a window stated only in the prose, which leaves a site reading a table that looks absolute. The template is explicit that "allowable windows should be stated for all visits and procedures" — all of them, in the table. The second is a window that disagrees with the one in section 8, which is the subject of the next section and the most common finding on a first draft.

The footnotes are where the protocol usually breaks

Footnotes carry everything a grid of ticks cannot: that a procedure is done only for participants of childbearing potential, that a sample is taken before dosing, that a window differs after a given visit. They are written last, read least, and copied wholesale from the past protocol more often than any other part of the table.

The sample draft carries a textbook instance. Section 8.1 says visit windows are plus or minus three days through Week 16 and plus or minus seven thereafter — which matches the synopsis. The schedule's footnote, inherited from the earlier study, allows plus or minus seven days for every visit after Day 1. Both statements are defensible in isolation. Together they mean a Week 12 visit held five days late is compliant by the footnote and a deviation by section 8.1, and nobody finds out until a monitor asks.

A window that disagrees with its own footnote, with both passages shown

Section 8 of the sample draft open in Clinical Protocol Authoring with the consistency checks panel on the right. One finding is marked fixed: the primary endpoint week was missing from the schedule, accepted by Lena Ortiz and saved as version 0.2. Two medium findings remain. The first, across sections 5 and 9, reports that the contraception period differs between sections — section 5.1 asks for 20 weeks after the last dose while section 9.4 still says 16 weeks, reused from the earlier study — and shows both draft passages with a suggested fix. The second, across section 8 and the schedule, reports that visit windows disagree: section 8.1 allows plus or minus 3 days through Week 16 while the schedule footnote allows plus or minus 7 days for every visit after Day 1.
Sample protocol data in Clinical Protocol Authoring. Each finding shows both passages and one proposed fix; the fix is proposed, never applied, and the writer accepts it or dismisses it with a reason.

A practical habit: write the footnotes before the ticks. If a footnote cannot be written without naming a section, that is a sign the exception belongs in the prose and the table needs another row instead.

Every endpoint needs a visit: the check nobody runs by hand

The single most valuable test of a schedule takes one pass and is almost never done. For each endpoint in section 3, find the timepoint; find that visit's column; confirm the measurement is ticked there. It is tedious, which is why it slips, and it catches the most expensive class of error there is.

The sample draft failed it on its first morning. Its schedule was adapted from VLT-201, a Phase 2 study whose primary endpoint sat at Week 12. VLT-302's co-primary endpoints are PASI 90 and sPGA 0/1 at Week 16. The adapted table carried PASI, sPGA and BSA at every visit it had carried them at before — and not at Week 16. The protocol defined endpoints it had no means of measuring, and the draft was two minutes old.

A Phase 2 schedule adapted to a Phase 3 trial: the timepoint that moved

VLT-201 · Phase 2, the schedule this table was adapted fromprimary at Week 12
To primaryWk 12
  • To primaryWk 12
VLT-302 · Phase 3, the trial being writtenco-primary at Week 16
To co-primaryWk 16
MaintenanceWk 52
Follow-upWk 60
  • To co-primaryWk 16
  • MaintenanceWk 52
  • Follow-upWk 60
Sample protocol data in Clinical Protocol Authoring, drawn to scale in weeks from Day 1. The earlier study measured its primary endpoint at Week 12; the new trial measures co-primary endpoints at Week 16, then continues to the Week 52 database lock and a Week 60 safety visit. The inherited table carried efficacy at every visit it used to — and the one visit the new trial exists to measure was not one of them.

Four other cross-checks belong in the same pass, and all four are mechanical. Does every eligibility test appear before randomisation? Does every dosing visit carry the intervention row? Does the number of visits in the table match the number the synopsis states? Does any visit carry a procedure that no endpoint and no safety rule requires — the question that decides what may be cut when a visit runs long?

Screening, run-in, treatment, follow-up: one row per period

Above the visit columns, most schedules carry a period band: screening, any run-in or washout, treatment, follow-up. SPIRIT 2025 asks for exactly this at item 18 — the time schedule "including any run-ins and washouts" — and it earns its space for three reasons. It tells a reader where consent sits relative to the first procedure. It shows where the analysis sets of section 10 begin and end. And it makes the shape of the trial legible without reading a word.

The sample trial has four periods: screening up to five weeks, treatment from Day 1 through the last dose at Week 40, continued assessment to the Week 52 database lock, and a safety follow-up visit at Week 60. Each boundary is a sentence somewhere else in the protocol, and each is a place where a schedule inherited from a shorter study quietly keeps the wrong number of weeks.

SPIRIT 2025 item 18 and the ICH M11 schedule of activities: one table, two vocabularies

SPIRIT 2025, item 18ICH M11, section 1.3
What it asks for

SPIRIT 2025, item 18: "Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended."

ICH M11, section 1.3: "The schedule of activities must capture the procedures that will be accomplished at each trial visit, and all contact with participants (e.g., telephone contacts)." A tabular format is recommended.

What it calls it

SPIRIT 2025, item 18: Participant timeline — one of 34 minimum items for a randomised trial protocol.

ICH M11, section 1.3: Schedule of activities — section 1.3, inside the protocol summary, near the front of the document.

Where it is stricter

SPIRIT 2025, item 18: Names run-ins and washouts explicitly, and recommends a schematic diagram as well as the grid.

ICH M11, section 1.3: Requires allowable windows for all visits and procedures, and names the tests used for eligibility, randomisation, stratification and discontinuation decisions.

What a writer does

SPIRIT 2025, item 18: Draw the periods, including anything before first dose, and keep the diagram in step with the table.

ICH M11, section 1.3: Put a window on every column, and make the decision-making tests identifiable rather than buried in a group.

Left column from the SPIRIT 2025 statement, April 2025; right column from the ICH M11 template, Step 4. The last row is our reading. A protocol that satisfies one will nearly satisfy the other, but neither is a subset of the other.Source: SPIRIT 2025 (PMC); ICH M11 template

The table a site reads, and the burden it carries

A schedule can be entirely correct and still be a bad schedule, because correctness says nothing about what a column asks of one person on one day. ICH E8(R1) puts the point where it belongs — in design, not in monitoring: clinical investigators and potential participants "have valuable insights into the feasibility of enrolling participants who meet proposed eligibility criteria, whether scheduled study visits and procedures may be overly burdensome and lead to early dropouts".

Published benchmarks show how much a modern protocol asks. In a study of protocol design across phases, Phase III protocols carried the highest mean number of distinct procedures, 34.5, and the highest mean total procedures, 266.0, alongside the highest mean page count of 115.9; Phase II protocols carried the most endpoints, at a mean of 20.7.

What a Phase III protocol typically asks for

34.5

mean distinct procedures per Phase III protocol

266.0

mean total procedures per Phase III protocol

115.9

mean total pages per Phase III protocol

20.7

mean endpoints per Phase II protocol, the highest of any phase

Getz KA et al., 'Protocol Design and Performance Benchmarks by Phase and by Oncology and Rare Disease Subgroups', Therapeutic Innovation & Regulatory Science, 2022. Published means across phases, not a target and not a measured result of any software.Source: Getz et al., 2022 (PMC)

Against those means, a per-visit arithmetic is a cheap discipline. The sample trial scores each visit on minutes on site, millilitres of blood and needle sticks, with draws taken together counted once, and holds the result against a limit the sponsor sets. Day 1 is the hardest visit in the first draft: one hour fifty-five minutes, 21 mL and two sticks, which scores 59 against a limit of 60. The method, and the published limits that bound the blood half of it, are taken apart in blood draw limits for research.

One visit's arithmetic, procedure by procedure

A panel in Clinical Protocol Authoring headed Day 1, patient burden 59, for the invented study VLT-302. A table lists every procedure at that visit with its minutes, blood and needle sticks: eligibility criteria 10 minutes, PASI 10, sPGA 5, BSA 5, DLQI 5, vital signs 10, clinical laboratory tests 10 minutes and 12 millilitres as a shared draw, pregnancy test 5, adverse events 5, concomitant medication 5, pre-dose PK sample 4 millilitres as a shared draw, anti-drug antibodies 5 millilitres as a shared draw, the subcutaneous injection 30 minutes, and check-in and waiting 15 minutes. The total is 1 hour 55 minutes, 21 millilitres and 2 sticks. Below it the arithmetic is shown: score equals 0.25 times 115 minutes plus 0.6 times 21 millilitres plus 9 times 2 sticks equals 59, with draws taken together counted as one stick, against a limit of 60.
Sample protocol data in Clinical Protocol Authoring. The weights and the limit are the sponsor's settings, not a published standard; what matters is that the arithmetic is visible to the person deciding.

Who reviews the schedule before it goes out

Four readers, in this order, and each one is looking for something the others are not. The writer checks that every row has a home in the prose and every window matches it. Clinical operations checks that a site can actually run the column — rooms, staff, fasting, the order of procedures within the morning. The medical monitor checks that safety assessments are frequent enough and sit where a signal would appear. The statistician checks that every endpoint has a visit, and that the visits support the analysis timepoints in section 10.

Eight checks to run on a schedule before it goes to review

  1. Every endpoint in section 3 has a measurement ticked at its timepoint

    The cheapest check there is, and the one an adapted schedule fails most often.

  2. Every eligibility, stratification and discontinuation test is in the table, and before the decision it feeds

    Named explicitly by the ICH M11 instruction for section 1.3.

  3. Every visit column carries a window, and the same window appears in the prose

    Compare the footnote with section 8.1 line by line; this is the classic inherited mismatch.

  4. Every contact that is not a visit has a column

    Telephone calls, diaries and remote questionnaires included, as the template requires.

  5. The number of visits and the week of each match the synopsis

    If the synopsis is silent on a timepoint, that is an open question, not a default.

  6. Every dosing visit carries the intervention row, and every pre-dose sample is marked pre-dose

    A PK sample on the wrong side of the injection is an unusable result, not a deviation.

  7. Each visit has been added up: minutes, millilitres and sticks

    Do it before a site does it for you, after the first participants are enrolled.

  8. Every procedure traces to an endpoint, a safety requirement or a regulatory one

    Anything that traces to none of the three is the first thing to cut when a visit runs long.

Checks two, three and four follow directly from the ICH M11 instruction for section 1.3; the rest are our reading of what review sends back.

Trial processes should be operationally feasible and avoid unnecessary complexity, procedures and data collection. Trial processes should support the key trial objectives. The sponsor should not place unnecessary burden on participants and investigators.

ICH E6(R3), Good Clinical Practice, adopted 6 January 2025

In Clinical Protocol Authoring the table is the first screen, the checks run as the draft is written, and the fourteen sections draft beside it — so a change to a column is a change to the prose in the same breath. Where the schedule sits in the rest of the drafting order is set out in how to write a clinical trial protocol, and what the template changed about section numbering in the ICH M11 template. To see the whole table on one trial, start from Clinical Protocol Authoring.

Questions people ask

What does SoA stand for in a clinical trial?

Schedule of activities — the table of visits and procedures at section 1.3 of the ICH M11 protocol template. The same abbreviation is sometimes read as schedule of assessments, which is what many sponsor templates call it. Both refer to the same table; M11 uses activities, and the template's instruction appears under that heading.

Is the schedule of activities the same as the schedule of assessments?

In practice, yes. Sponsors have used schedule of assessments, schedule of events, study flow chart and participant timeline for the same grid. ICH M11 standardised on schedule of activities, ICH E6(R3) asks for "a description of the schedule of events", and SPIRIT 2025 calls it the participant timeline at item 18. If your template and your sponsor's house style differ, pick one and use it consistently, because a protocol that uses two names for one table will eventually be read as having two tables.

Where does the schedule of activities go in the protocol?

At section 1.3, inside the protocol summary, directly after the synopsis and the trial schema. That placement is deliberate: the template puts the information most needed to run the trial near the front, for investigators and site staff. Legacy sponsor templates often put it at the back as an appendix, which is one of the practical moves a template migration has to make.

How do you write footnotes in a schedule of assessments?

Number them against the cell or the column they qualify, keep each to one idea, and make each one testable: who it applies to, what changes, and from which visit. Avoid footnotes that restate a rule the prose owns — they drift. And check every footnote that states a window or a duration against the section that states the same thing, because footnotes are copied from past protocols more often than any other part of the table.

How many visits does a phase 3 trial have?

There is no standard number; it follows the endpoints and the treatment duration. The sample Phase 3 trial here has eleven, from screening to a safety follow-up at Week 60. Published benchmarks give a better sense of scale than a visit count: Phase III protocols carry a mean of 34.5 distinct procedures and 266.0 total procedures. A useful question is not how many visits there are but how many procedures each one carries that no endpoint or safety rule requires.

How do you check that every endpoint has a visit?

Take each endpoint from section 3 with its timepoint, find that visit's column, and confirm the measurement is ticked there — then do the reverse, and look for measurements that are ticked at visits no endpoint needs. Do it as a list rather than by eye, because the failure mode is an adapted schedule where almost everything is right. In the sample draft, the co-primary endpoints at Week 16 had no PASI, sPGA or BSA scheduled at that visit at all, inherited from a study whose primary endpoint sat at Week 12.

Clinical Protocol Authoring.
See it on your own files.

An agentic solution from Botminds. Trial protocols drafted in your template around the schedule of assessments, with every visit scored for patient burden. Book a demo, or explore how it works.